Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human LY3056480 for sensorineural hearing loss
ISRCTN59733689Phase 2Completed
- Sponsor
- Audion Therapeutics
- Start
- Sep 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of LY3056480 in sensorineural hearing loss (SNHL), sponsored by Audion Therapeutics. Primary endpoints: Procedure-related local and systemic adverse events and Systemic adverse events and clinically significant systemic changes. Started Sep 2017; status: completed.
02
Drugs
LY3056480
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on ISRCTN59733689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59733689.